Genoway (ALGEN) - Total Assets
Based on the latest financial reports, Genoway (ALGEN) holds total assets worth €38.82 Million EUR (≈ $45.39 Million USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Genoway - Total Assets Trend (2004–2024)
This chart illustrates how Genoway's total assets have evolved over time, based on quarterly financial data. Also see market cap of Genoway for the company's overall valuation and market capitalisation.
Genoway - Asset Composition Analysis
Current Asset Composition (December 2024)
Genoway's total assets of €38.82 Million consist of 54.9% current assets and 45.1% non-current assets. Review how much debt does Genoway carry to assess the company's total debt and financial obligations.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 15.6% |
| Accounts Receivable | €7.01 Million | 22.1% |
| Inventory | €1.09 Million | 3.4% |
| Property, Plant & Equipment | €5.56 Million | 17.5% |
| Intangible Assets | €5.58 Million | 17.5% |
| Goodwill | €196.95K | 0.6% |
Asset Composition Trend (2004–2024)
This chart illustrates how Genoway's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See current stock price of Genoway for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Genoway's current assets represent 54.9% of total assets in 2024, an increase from 0.0% in 2004.
- Cash Position: Cash and equivalents constituted 15.6% of total assets in 2024, down from 40.6% in 2004.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 17.0% of total assets, an increase from 5.0% in 2004.
- Asset Diversification: The largest asset category is accounts receivable at 22.1% of total assets.
Genoway Competitors by Total Assets
Key competitors of Genoway based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Dianthus Therapeutics Inc.
NASDAQ:DNTH
|
USA | $1.21 Billion |
|
Tango Therapeutics Inc
NASDAQ:TNGX
|
USA | $1.07 Billion |
|
Damora Therapeutics, Inc.
NASDAQ:DMRA
|
USA | $543.64 Million |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
|
Wecome Pharmaceutical Co Ltd
SHE:300878
|
China | CN¥1.49 Billion |
|
Tectonic Therapeutic, Inc.
NASDAQ:TECX
|
USA | $246.58 Million |
|
Relmada Therapeutics Inc
NASDAQ:RLMD
|
USA | $235.36 Million |
Genoway - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.50 | 1.99 | 2.26 |
| Quick Ratio | 2.30 | 1.87 | 2.12 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €10.27 Million | €8.58 Million | €8.32 Million |
Genoway - Advanced Valuation Insights
This section examines the relationship between Genoway's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.24 |
| Latest Market Cap to Assets Ratio | 0.98 |
| Asset Growth Rate (YoY) | -0.1% |
| Total Assets | €31.80 Million |
| Market Capitalization | $31.09 Million USD |
Valuation Analysis
Near Book Valuation: The market values Genoway's assets close to their book value (0.98x), suggesting investors view the company's assets at approximately fair value.
Slight Asset Contraction: Genoway's assets decreased by 0.1% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Genoway (2004–2024)
The table below shows the annual total assets of Genoway from 2004 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | €31.80 Million ≈ $37.18 Million |
-0.13% |
| 2023-12-31 | €31.84 Million ≈ $37.23 Million |
-3.28% |
| 2022-12-31 | €32.92 Million ≈ $38.49 Million |
+1.31% |
| 2021-12-31 | €32.50 Million ≈ $37.99 Million |
+17.88% |
| 2020-12-31 | €27.57 Million ≈ $32.23 Million |
+43.94% |
| 2019-12-31 | €19.15 Million ≈ $22.39 Million |
-2.72% |
| 2018-12-31 | €19.69 Million ≈ $23.02 Million |
+14.68% |
| 2017-12-31 | €17.17 Million ≈ $20.07 Million |
+46.73% |
| 2016-12-31 | €11.70 Million ≈ $13.68 Million |
+8.58% |
| 2015-12-31 | €10.78 Million ≈ $12.60 Million |
+3.84% |
| 2014-12-31 | €10.38 Million ≈ $12.13 Million |
+6.46% |
| 2013-12-31 | €9.75 Million ≈ $11.40 Million |
-7.50% |
| 2012-12-31 | €10.54 Million ≈ $12.32 Million |
-4.27% |
| 2011-12-31 | €11.01 Million ≈ $12.87 Million |
-3.69% |
| 2010-12-31 | €11.43 Million ≈ $13.36 Million |
+2.33% |
| 2009-12-31 | €11.17 Million ≈ $13.06 Million |
+9.22% |
| 2008-12-31 | €10.23 Million ≈ $11.96 Million |
-0.63% |
| 2007-12-31 | €10.29 Million ≈ $12.03 Million |
+45.41% |
| 2006-12-31 | €7.08 Million ≈ $8.27 Million |
+60.72% |
| 2005-12-31 | €4.40 Million ≈ $5.15 Million |
-18.61% |
| 2004-12-31 | €5.41 Million ≈ $6.33 Million |
-- |
About Genoway
genOway Société anonyme, a biotechnology company, engages in the development and commercialization of custom genetically modified mouse, rat, and cell line models worldwide. It produces customized mouse models, such as knockout (KO) and knockin (KI) mouse models; customized rat models, including constitutive and conditional KO, point mutation KI, and quick KI rat models; and customized cell lines… Read more